SABS.US SAB Biotherapeutics Inc

Healthcare Biotechnology USA Stocks
3.00 USD
Close of Nov 17, 2026
2.44 5.15
Market cap
USD 270M
P/E
-
P/B
1.26x
ROE
-40.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SABS.US undervalued?

Graham number

The Graham number of SAB Biotherapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SAB Biotherapeutics Inc fundamental analysis

No fundamental analysis for SAB Biotherapeutics Inc yet.

SAB Biotherapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SAB Biotherapeutics Inc

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartere…

Full company profile